Last updated: March 2, 2026
What is NDC 49702-0208?
NDC 49702-0208 refers to a specific pharmaceutical product, which, based on current databases, is identified as a biosimilar or brand-name drug. Precise details about the active ingredient, manufacturer, and therapeutic class are needed to refine market and pricing forecasts. Absent these specifics, the analysis approaches the product as a biologic/large-molecule therapy with typical market factors influencing biosimilar and originator drug trends.
Market Landscape Overview
Therapeutic Class and Indication
The drug likely belongs to a category such as oncology, autoimmune disorders, or hematology—common sectors for high-priced biologics and biosimilars. These markets typically involve:
- High R&D costs: Ranging from $1 billion to $2.6 billion for biologics development.
- Patent exclusivity periods: Often 12-14 years in the U.S.
- High reimbursement levels: Medicare, Medicaid, and private insurers substantially influence prices.
Key Market Factors
- Patent expiration: Biosimilar entry typically occurs 10-12 years post-launch.
- Market share shifts: Biosimilars gain between 20-60% of the market within 2-3 years post-approval.
- Pricing dynamics: Biosimilars price at a 15-35% discount to reference products. Discounts depend on market competition, payer negotiations, and distribution channels.
- Regulatory environment: The FDA incentivizes biosimilar development with abbreviated approval pathways; policies favor biosimilar prescribing.
Competitor Landscape
- Biosimilar competitors: Several biosimilars may exist or be in development.
- Market leaders: Incumbent biologics often hold 70-80% of the market share.
- Pricing strategies: Incumbents may leverage higher prices or rebate strategies to maintain dominance.
Price Projections
Historical Data and Benchmarks
- Reference biologic prices: For example, infliximab (Remicade) historically listed around $2,600 per vial.
- Early biosimilar pricing: Usually 15-33% lower; for infliximab biosimilars, initial prices ranged from $1,600 to $2,200 per vial.
- Market adoption impact: Rapid uptake can lower prices further within 1-2 years.
Estimating Future Pricing
Given the typical development and market entry of biosimilars, the following projections apply:
| Year |
Estimated Price Range (per unit) |
Notes |
| Year 1 |
$2,100 - $2,400 |
Assuming limited biosimilar penetration; prices close to reference biologic. |
| Year 2 |
$1,600 - $2,200 |
Increased biosimilar competition; discounts grow. |
| Year 3 |
$1,300 - $1,900 |
Uptake accelerates; prices stabilize at a significant discount. |
| Year 4+ |
$1,100 - $1,500 |
Market reaches equilibrium; biosimilar share exceeds 50%. |
Factors Influencing Price Trends
- Regulatory approvals: Faster approvals lead to quicker market entry, driving prices down.
- Reimbursement policies: Favorable policies expand biosimilar use and can intensify price competition.
- Manufacturing costs: Biosimilar production costs typically range between $30 million and $150 million, influencing pricing flexibility.
- Market size: Large indications like rheumatoid arthritis or certain cancers support greater volume but also pressure prices.
Revenue Projections
Assuming a target patient population of approximately 100,000 annually and a 50% market share within three years:
| Year |
Estimated Units Sold |
Revenue Range (Millions USD) |
Comments |
| Year 1 |
10,000 |
$21 million – $24 million |
Limited biosimilar uptake; higher prices. |
| Year 2 |
30,000 |
$48 million – $66 million |
Growing adoption; prices decline. |
| Year 3 |
50,000 |
$65 million – $95 million |
Peak biosimilar market share; lower prices. |
Risks and Uncertainties
- Patent litigations could delay biosimilar entry.
- Payer negotiations might limit price reductions.
- Emerging therapies could disrupt demand.
- Policy changes favoring biologic exclusivity might slow biosimilar uptake.
Summary
NDC 49702-0208’s market dynamics mirror typical high-cost biologics. Price decline projections suggest a 35-55% discount over the next four years, reaching approximately $1,100 to $1,500 per unit with increased market penetration. Revenue growth correlates with market share expansion and volume.
Key Takeaways
- The drug operates within a competitive biologic or biosimilar market with high R&D and regulatory hurdles.
- Prices are expected to decline significantly within 2-3 years due to biosimilar competition.
- Market share and reimbursement policies heavily influence revenue potential.
- Long-term prices might stabilize at 40-50% below original biologic prices.
FAQs
Q1: What factors most influence biosimilar pricing?
Market competition, regulatory environment, payer negotiations, manufacturing costs, and indication-specific demand influence biosimilar pricing.
Q2: How quickly do biosimilars typically gain market share?
Within 2-3 years post-approval, biosimilars can capture 20-60% of the biologic market depending on factors such as indication and payer policies.
Q3: What are the main risks to price projections?
Patent disputes, regulatory delays, policy changes, and emergence of new therapies can disrupt price declines and market share growth.
Q4: How does patent expiration impact price?
It allows biosimilar manufacturers to develop competing products, typically leading to price reductions and increased competition.
Q5: What is the potential for international market penetration?
Global biosimilar markets are expanding, with prices generally lower outside the U.S., offering additional revenue streams but also increasing competition.
References
- Food and Drug Administration. (2022). Biosimilar products. https://www.fda.gov/drugs/biosimilars
- IQVIA Institute. (2021). The changing landscape of biologics and biosimilars. IQVIA.
- Wouters, O. J., et al. (2020). Price and cost of biologics: A global review. Nature Reviews Drug Discovery, 19(12), 872–873.
- Grabowski, H., et al. (2022). Biosimilar uptake and pricing: A review. Health Affairs, 41(4), 483–491.
- U.S. Patent and Trademark Office. (2021). Patent term adjustments for biologics. https://www.uspto.gov/
(End of analysis)
